Related Experiment Video
Updated: Feb 2, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer
Hervé Bischoff1, Thierry Petit1
1Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Abstract:
HR +/HER2 + breast cancer (BC) represents a unique clinical entity distinct from HR-/HER2 + BC, with specific molecular characteristics and resistance mechanisms. The interaction between estrogen receptor (ER) and HER2 signaling pathways promotes tumor growth and therapeutic resistance, highlighting the need for tailored approaches. This review focuses on the clinical and molecular features of HR + /HER2 + metastatic BC, with an emphasis on recent data exploring the integration of CDK4/6 inhibitors (CDK4/6i) into anti-HER2 therapeutic strategies. Key findings from metastatic trials are summarized. HR + /HER2 + metastatic BC is characterized by a predominance of luminal molecular subtypes, associated with distinct patterns of metastatic spread and prolonged progression-free survival compared to nonluminal subtypes. Despite the efficacy of dual HER2 blockade, resistance remains a challenge, driven by crosstalk between ER and HER2 pathways. CDK4/6i disrupt the cell cycle at the G1/S checkpoint and have shown promise in overcoming resistance, inducing sustained senescence, and improving outcomes in luminal subtypes. Recent trials suggest that CDK4/6i may play a key role in maintenance therapy and chemotherapy-free regimens for selected patients with HR + /HER2 + metastatic BC. The integration of CDK4/6 inhibitors into anti-HER2 treatment strategies represents a promising approach to address the unique biology of HR + /HER2 + BC. Molecular profiling and personalized treatment strategies are essential to optimize patient outcomes and reduce unnecessary toxicity.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Position and Displacement
Serial Position Effect
Position Vectors
For instance, we want to locate a point P(x, y, z) relative to the origin of coordinates O. In that case, we can define a position...

